Real-world usage pattern, effectiveness and safety of oral tramadol/dexketoprofen trometamol fixed-dose combination in moderate-to-severe acute pain in Asia: a prospective, multicentre, observational study

BMJ Open. 2024 Oct 17;14(10):e090926. doi: 10.1136/bmjopen-2024-090926.

Abstract

Objectives: This study aims to determine the usage pattern, effectiveness and safety of oral tramadol 75 mg and dexketoprofen trometamol 25 mg fixed-dose combination (TRAM/DKP FDC) in the short-term treatment of moderate-to-severe acute pain in real-world clinical practice in Asia.

Design: Real-world, prospective, multicentre, observational, phase IV study.

Setting: 13 tertiary-care hospital sites across the Philippines, Thailand, Malaysia and Singapore.

Participants: Adult patients aged 18-80 years prescribed TRAM/DKP FDC for the short-term (up to 5 days) treatment of moderate-to-severe acute pain.

Main outcome measures: Primary endpoints were the proportion of patients prescribed TRAM/DKP FDC with different types of postsurgical and non-surgical treatments, and the average dosing frequency and duration of TRAM/DKP FDC treatment. Secondary endpoints were the proportion of patients achieving ≥30% pain reduction at 8 hours post the first dose (pain severity was assessed using the 11-point Numeric Pain Rating Scale); patient satisfaction at the end of treatment (based on a 5-point Patient Global Evaluation Scale (PGE)) and safety including the incidence of adverse drug reactions (ADRs).

Results: Among 599 patients (median age 44 years, 61.3% female) enrolled in this study, 68.61% (n=411) were postsurgical and 31.39% (n=188) were non-surgical patients. TRAM/DKP FDC was prescribed in a diverse group of postsurgical patients (eg, orthopaedic, general and cancer surgery) as well as in non-surgical conditions (eg, lower back pain and musculoskeletal pain). In the majority of patients, TRAM/DKP FDC was prescribed every 8 hours (65.94%) and for 5 days (78.80%). There was a significant reduction in pain intensity throughout the study and 65% of patients achieved ≥30% pain reduction from baseline at 8 hours post the first dose of TRAM/DKP FDC on day 1. 95.69% of patients were satisfied with the treatment (rated good, very good and excellent on the PGE scale). Overall, 13.9% of patients reported ADRs; most were mild to moderate in severity. The most common ADRs were nausea, vomiting and dizziness.

Conclusion: This study showed that TRAM/DKP FDC was used in diverse types of postsurgical and non-surgical patients in the real-world setting in Asia. It effectively reduced pain and was well tolerated with a high level of patient satisfaction.

Keywords: anaesthetics; back pain; medicine; pain management.

Publication types

  • Multicenter Study
  • Observational Study
  • Clinical Trial, Phase IV

MeSH terms

  • Acute Pain* / drug therapy
  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Analgesics, Opioid* / administration & dosage
  • Analgesics, Opioid* / adverse effects
  • Analgesics, Opioid* / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Asia
  • Drug Combinations
  • Female
  • Humans
  • Ketoprofen* / administration & dosage
  • Ketoprofen* / adverse effects
  • Ketoprofen* / analogs & derivatives
  • Ketoprofen* / therapeutic use
  • Malaysia
  • Male
  • Middle Aged
  • Pain Measurement*
  • Pain, Postoperative / drug therapy
  • Patient Satisfaction / statistics & numerical data
  • Philippines
  • Prospective Studies
  • Singapore
  • Thailand
  • Tramadol* / administration & dosage
  • Tramadol* / adverse effects
  • Tramadol* / therapeutic use
  • Treatment Outcome
  • Tromethamine* / administration & dosage
  • Tromethamine* / adverse effects
  • Tromethamine* / therapeutic use
  • Young Adult

Substances

  • Ketoprofen
  • dexketoprofen trometamol
  • Tramadol
  • Tromethamine
  • Analgesics, Opioid
  • Anti-Inflammatory Agents, Non-Steroidal
  • Drug Combinations